Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.91 USD | +5.66% | -8.23% | -32.98% |
05-13 | Morgan Stanley Lowers Price Target on NeuroPace to $9.50 From $13, Keeps Equalweight Rating | MT |
05-08 | NeuroPace, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Sales 2024 * | 75.85M 103M | Sales 2025 * | 89.24M 122M | Capitalization | 199M 271M |
---|---|---|---|---|---|
Net income 2024 * | -33M -44.95M | Net income 2025 * | -29M -39.5M | EV / Sales 2024 * | 2.92 x |
Net Debt 2024 * | 22.63M 30.82M | Net Debt 2025 * | 43.9M 59.79M | EV / Sales 2025 * | 2.72 x |
P/E ratio 2024 * |
-5.94
x | P/E ratio 2025 * |
-6.9
x | Employees | 181 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 80.19% |
Latest transcript on NeuroPace, Inc.
1 day | +5.66% | ||
1 week | -8.23% | ||
1 month | -50.29% | ||
3 months | -56.79% | ||
6 months | -22.36% | ||
Current year | -32.98% |
Managers | Title | Age | Since |
---|---|---|---|
Joel Becker
CEO | Chief Executive Officer | 56 | 23-07-09 |
Rebecca Kuhn
FOU | Founder | 64 | 97-11-18 |
Frank Fischer
FOU | Founder | 82 | 97-11-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Lisa Andrade
BRD | Director/Board Member | 52 | 21-10-31 |
Joseph Lacob
BRD | Director/Board Member | 68 | 97-11-18 |
Frank Fischer
FOU | Founder | 82 | 97-11-30 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 6.91 | +5.66% | 67,182 |
24-05-30 | 6.54 | -2.97% | 140,664 |
24-05-29 | 6.74 | -4.94% | 166,131 |
24-05-28 | 7.09 | -5.84% | 106,888 |
Delayed Quote Nasdaq, May 31, 2024 at 04:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-32.98% | 199M | |
+7.01% | 217B | |
+11.01% | 190B | |
+19.20% | 143B | |
+30.79% | 111B | |
+1.48% | 64.59B | |
+13.95% | 52.36B | |
-0.16% | 48.45B | |
-6.20% | 38.03B | |
+0.91% | 35.6B |
- Stock Market
- Equities
- NPCE Stock